(Q41526500)

2 October 2017

1 reference

title

Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities (English)

1 reference

methicillin-resistant Staphylococcus aureus

2 October 2017

main subject

0 references

vancomycin

1 reference

inferred from title

Staphylococcus aureus

1 reference

M Michel

1

1 reference

2 October 2017

L Gutmann

series ordinal

2

1 reference

2 October 2017

language of work or name

English

0 references

publication date

1 June 1997

1 reference

2 October 2017

1 reference

2 October 2017

volume

349

1 reference

2 October 2017

issue

9069

1 reference

2 October 2017

page(s)

1901-1906

1 reference

Methicillin-resistant Staphylococcus aureus: implications for the 1990s and effective control measures.

2 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Molecular aspects of methicillin resistance in Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Farm animals as a putative reservoir for vancomycin-resistant enterococcal infection in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Vancomycin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Emergence of Antibiotic Resistance In Hospitals, 1935-1975

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Methicillin-resistant staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Methicillin-resistant Staphylococcus aureus in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Staphylococcus aureus penicillin-binding protein 4 and intrinsic beta-lactam resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Origin and evolution of DNA associated with resistance to methicillin in staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Expression of resistance to methicillin.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

New mechanism for methicillin resistance in Staphylococcus aureus: clinical isolates that lack the PBP 2a gene and contain normal penicillin-binding proteins with modified penicillin-binding capacity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

World-wide antibiotic resistance in methicillin-resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Fusidic acid alone or in combination with vancomycin for therapy of experimental endocarditis due to methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Single- and combination-antibiotic therapy for experimental endocarditis caused by methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Treatment of severe staphylococcal infections with cefotaxime and fosfomycin in combination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Beta-lactam resistance mechanisms of methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

In vitro and in vivo antistaphylococcal activities of L-695,256, a carbapenem with high affinity for the penicillin-binding protein PBP 2a.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

In-vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Treatment of methicillin-resistant Staphylococcus aureus infection with quinupristin/dalfopristin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Identification of chromosomal location of mupA gene, encoding low-level mupirocin resistance in staphylococcal isolates.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Major trends in the microbial etiology of nosocomial infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Glycopeptide-resistant Enterococcus faecium outside Hospitals: a commentary.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Serious infections caused by multiply-resistant Enterococcus faecium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Bacterial resistance to the cyclic glycopeptides.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Glycopeptide resistance in enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Current perspectives on glycopeptide resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Modification of peptidoglycan precursors is a common feature of the low-level vancomycin-resistant VANB-type Enterococcus D366 and of the naturally glycopeptide-resistant species Lactobacillus casei, Pediococcus pentosaceus, Leuconostoc mesenteroide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Peptidoglycan synthesis and structure in Staphylococcus haemolyticus expressing increasing levels of resistance to glycopeptide antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Triple combination penicillin-vancomycin-gentamicin for experimental endocarditis caused by a highly penicillin-and glycopeptide-resistant isolate of Enterococcus faecium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Comparison of different beta-lactam-glycopeptide-gentamicin combinations for an experimental endocarditis caused by a highly beta-lactam-resistant and highly glycopeptide-resistant isolate of Enterococcus faecium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Synergy and resistance to synergy between beta-lactam antibiotics and glycopeptides against glycopeptide-resistant strains of Enterococcus faecium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Antibiotic treatment of experimental endocarditis due to vancomycin- and ampicillin-resistant Enterococcus faecium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Effective treatment of multidrug-resistant enterococcal experimental endocarditis with combinations of cell wall-active agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

In-vitro synergy and mechanism of interaction between vancomycin and ciprofloxacin against enterococcal isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

In vitro activity of RP 59500 (quinupristin/dalfopristin) and ramoplanin against vancomycin-resistant Enterococcus faecium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Quinupristin/dalfopristin (RP 59500) therapy for vancomycin-resistant Enterococcus faecium aortic graft infection: case report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Treatment of vancomycin-resistant Enterococcus faecium infections with an investigational streptogramin antibiotic (quinupristin/dalfopristin): a report of fifteen cases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

In-vitro activity of two glycylcyclines against enterococci resistant to other agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

In vitro and in vivo activities of clinafloxacin, CI-990 (PD 131112), and PD 138312 versus enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

Enteric eradication of vancomycin-resistant Enterococcus faecium with oral bacitracin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2911192-2

7 January 2021

10.1016/S0140-6736(96)11192-2

Identifiers

DOI

1 reference

2 October 2017

1 reference